BioSpace News Archive

The scope of an exceptional Pseudotumor Cerebri market report can be expanded from market scenarios to comparative pricing between major players.

Porcine Vaccines Market study by “Data Bridge Market Research” provides details about the market dynamics affecting the Porcine Vaccines market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in a fireside chat and 1x1 meetings at the William Blair Biotech Focus Conference 2022.

Cytokinetics, Incorporated announced that on June 30, 2022 it granted stock options to purchase an aggregate of 180,450 shares of common stock to 19 new employees, whose employment commenced in June 2022, as a material inducement to their employment.

Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TNFα in biologic-naïve patients with moderate-to-severe ulcerative colitis.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wednesday, July 6, 2022 at 8:30am Eastern Time, the Company will host a webcast and conference call to share new functional data across multiple studies from the clinical development program for SRP-9001 (delandistrogene moxeparvovec) for the treatment of Duchenne muscular dystrophy.

MediWound Ltd. announced that it will host an in-person key opinion leader event on EscharEx for analysts and investors on Tuesday, July 12, 2022 at 8:00 am Eastern Time at the St. Regis Hotel in New York, NY.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to a new non-executive employee to purchase an aggregate of 7,000 shares of common stock.

Hologic, Inc. announced that the Company plans to release its financial results for the third quarter of fiscal 2022 on Wednesday, July 27, after the market closes.

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointments of Edward Hu and Kate Hermans to its Board of Directors.